SynthesisEuropean journal of clinical pharmacology2025
Effectiveness and safety of concomitant use of direct oral anticoagulants and antiarrhythmic drugs: a systematic review of observational studies.
Synthesis in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConcomitant use of antiarrhythmic drugs (AAs) may affect the effectiveness and safety of direct oral anticoagulants (DOACs) through pharmacokinetic interactions and other factors. Our systematic review aimed to provide an in-depth methodological assessment and synthesis of the available real-world evidence in the area.
methodsWe systematically searched MEDLINE/PubMed and EMBASE from January 2011 to October 2024 for observational studies assessing the effectiveness (risk of stroke) and safety (risk of major bleeding) associated with concomitant use of DOACs and AAs. We assessed the risk of bias using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool.
resultsWe identified 17 relevant studies including overall 2,613,693 patients. For stroke, all six studies showed no increased risk associated with concomitant use of DOACs and AAs. For major bleeding, seven studies showed an increased risk associated with concomitant use of DOACs and AAs (up to 187%), four studies showed heterogeneous results depending on the specific AA, and six studies showed no increased risk. When considering only higher-quality studies (n = 6), there was no association with the risk of stroke (n = 3). There were associations with an increased risk of major bleeding for concomitant use of DOACs and diltiazem (n = 2) or verapamil (n = 1), while findings for concomitant use of DOACs and amiodarone were inconsistent (n = 3).
conclusionsBased on the synthesis of higher-quality real-world evidence, concomitant use of AAs does not seem to impact the effectiveness of DOACs. Findings on safety possibly depend on the specific AA, with diltiazem showing the highest risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.